Pelvic Inflammatory Disease (PID) Treatment Global Market Report 2025

The pelvic inflammatory disease (PID) treatment market size has grown strongly in recent years. It will grow from $4.49 billion in 2024 to $4.75 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the growing adoption of telemedicine, the rising incidence of sexually transmitted infections (STIs), increasing awareness of pelvic inflammatory disease (PID), and higher healthcare expenditure.

The pelvic inflammatory disease (PID) treatment market size is expected to see strong growth in the next few years. It will grow to $5.88 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth during the forecast period can be attributed to the increasing prevalence of sexually transmitted infections (STIs), rising awareness regarding women's reproductive health, growing awareness of pelvic inflammatory disease (PID), increasing reliance on telehealth services, and a rising incidence of STIs. Key trends expected during this period include innovative PID treatment products, advancements in diagnostic technologies, innovations in personalized treatment, advanced imaging techniques, and other technological advancements.

The rising prevalence of sexually transmitted infections (STIs) is expected to drive the growth of the pelvic inflammatory disease (PID) treatment market. STIs are infections caused by bacteria, viruses, or parasites that are primarily spread through sexual contact, including vaginal, anal, or oral sex. The increasing prevalence of STIs is attributed to factors such as risky sexual behaviors, unprotected sex, lack of awareness, and delayed testing and treatment. PID treatment is crucial for managing STIs, as it involves the use of antibiotics to eliminate the bacteria causing the infection, preventing complications such as chronic pelvic pain and infertility, and reducing the risk of recurrent infections. For example, in October 2024, a report from the UK Health Security Agency (UKHSA) revealed that in 2023, England recorded 6,008 new HIV diagnoses, marking a 51% increase compared to 3,975 in 2022. Therefore, the growing prevalence of STIs is driving the expansion of the PID treatment market.

Companies operating in the pelvic inflammatory disease (PID) treatment market are focusing on developing innovative formulations, such as probiotic supplements, to enhance treatment efficacy, restore vaginal microbiota balance, and reduce the recurrence of infections in PID patients. Probiotic supplements contain beneficial live bacteria or yeasts that help maintain or restore a healthy balance of the gut and vaginal microbiota. For example, in November 2024, Lee Health Domain, an India-based pharmaceutical company, launched V-Ferin, a probiotic supplement aimed at supporting vaginal health. Formulated with Lactobacillus acidophilus, lactoferrin peptide, and cranberry extract, V-Ferin seeks to restore the natural microbiome and prevent common vaginal infections such as bacterial vaginosis and yeast infections. With approximately 25-30% of women affected by these conditions, which can lead to PID if left untreated, V-Ferin offers an innovative solution to improve health and prevent complications.

In February 2022, Mankind Pharma Limited, an India-based pharmaceutical company, acquired Panacea Biotec Limited (PBL) for $212.88 million. This acquisition strengthens Mankind Pharma's position in the chronic and transplant business by integrating well-researched formulations and leveraging advanced technology and niche expertise, while retaining Panacea Biotec's sales and marketing team to ensure seamless business operations and market expansion. Panacea Biotec Limited is an India-based biotechnology company that develops, manufactures, and commercializes pharmaceuticals, vaccines, and biosimilars for various diseases, including pelvic inflammatory disease (PID).

Major players in the pelvic inflammatory disease (PID) treatment market are Pfizer Inc., Bayer AG, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Hetero Drugs Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Mayne Pharma Group Limited, Saphnix Lifesciences, Aristo Pharmaceuticals Pvt. Ltd., Zydus Cadila Healthcare Ltd., and Amagen India Life Sciences.

North America was the largest region in the pelvic inflammatory disease (PID) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pelvic inflammatory disease (PID) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pelvic inflammatory disease (PID) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pelvic inflammatory disease (PID) treatment involves the medical management of infections affecting the female reproductive organs, typically caused by sexually transmitted bacteria such as Chlamydia trachomatis and Neisseria gonorrhoeae. The goal of treatment is to eliminate the infection, alleviate symptoms, and prevent complications such as infertility, chronic pelvic pain, and ectopic pregnancy.

The main types of PID treatment include antibiotic therapy, surgery, pain management, and hormonal therapy. Antibiotic therapy involves using antibiotics to treat bacterial infections by killing or inhibiting the growth of bacteria. It can be administered orally, intravenously, or intramuscularly, and PID treatment is available in hospitals, clinics, and home care settings.

The pelvic inflammatory disease (PID) treatment market research report is one of a series of new reports that provides pelvic inflammatory disease (PID) treatment market statistics, including the pelvic inflammatory disease (PID) treatment industry global market size, regional shares, competitors with the pelvic inflammatory disease (PID) treatment market share, detailed pelvic inflammatory disease (PID) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the pelvic inflammatory disease (PID) treatment industry. This pelvic inflammatory disease (PID) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pelvic inflammatory disease (PID) treatment market consists of revenues earned by entities by providing services such as medication therapy, pain management, and hospital and clinic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pelvic inflammatory disease (PID) treatment market includes sales of antibiotics, pain relievers, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.